A BILL 
To direct the Comptroller General of the United States to 
submit a report describing the response of certain enti-
ties to the COVID–19 pandemic with respect to the 
development, regulatory evaluation, and deployment of 
diagnostic tests. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. GAO REPORT ON DIAGNOSTIC TESTS. 
3
(a) GAO STUDY.—Not later than 18 months after 
4
the date of enactment of this Act, the Comptroller General 
5
of the United States shall submit to the Committee on 
6
Energy and Commerce of the House of Representatives 
7
01:49 May 30, 2020
H6839
2 
•HR 6839 IH
and the Committee on Health, Education, Labor and Pen-
1
sions of the Senate a report describing the response of 
2
entities described in subsection (b) to the COVID–19 pan-
3
demic with respect to the development, regulatory evalua-
4
tion, and deployment of diagnostic tests. 
5
(b) ENTITIES DESCRIBED.—Entities described in 
6
this subsection include— 
7
(1) laboratories, including public health, aca-
8
demic, clinical, and commercial laboratories; 
9
(2) diagnostic test manufacturers; 
10
(3) State, local, Tribal, and territorial govern-
11
ments; and 
12
(4) the Food and Drug Administration, the 
13
Centers for Disease Control and Prevention, the 
14
Centers for Medicare & Medicaid Services, the Na-
15
tional Institutes of Health, and other relevant Fed-
16
eral agencies, as appropriate. 
17
(c) CONTENTS.—The report under subsection (a) 
18
shall include— 
19
(1) a description of actions taken by entities de-
20
scribed in subsection (b) to develop, evaluate, and 
21
deploy diagnostic tests; 
22
(2) an assessment of the coordination of Fed-
23
eral agencies in the development, regulatory evalua-
24
tion, and deployment of diagnostic tests; 
25
01:49 May 30, 2020
H6839
3 
•HR 6839 IH
(3) an assessment of the standards used by the 
1
Food and Drug Administration to evaluate diag-
2
nostic tests; 
3
(4) an assessment of the clarity of Federal 
4
agency guidance related to testing, including the 
5
ability for individuals without medical training to 
6
understand which diagnostic tests had been evalu-
7
ated by the Food and Drug Administration; 
8
(5) a description of— 
9
(A) actions taken and clinical processes 
10
employed by States and territories that have 
11
authorized laboratories to develop and perform 
12
diagnostic tests not authorized, approved, or 
13
cleared by the Food and Drug Administration, 
14
including actions of such States and territories 
15
to evaluate the accuracy and sensitivity of such 
16
tests; and 
17
(B) the standards used by States and ter-
18
ritories when deciding when to authorize labora-
19
tories to develop or perform diagnostic tests; 
20
(6) an assessment of the steps taken by labora-
21
tories and diagnostic test manufacturers to validate 
22
diagnostic tests, as well as the evidence collected by 
23
such entities to support validation; and 
24
01:49 May 30, 2020
H6839
4 
•HR 6839 IH
(7) based on available reports, an assessment of 
1
the accuracy and sensitivity of a representative sam-
2
ple of available diagnostic tests. 
3
(d) DEFINITION.—In this section, the term ‘‘diag-
4
nostic test’’ means an in vitro diagnostic product (as de-
5
fined in section 809.3(a) of title 21, Code of Federal Regu-
6
lations) for— 
7
(1) the detection of SARS–CoV–2; 
8
(2) the diagnosis of the virus that causes 
9
COVID–19; or 
10
(3) the detection of antibodies specific to 
11
SARS–CoV–2, such as a serological test. 
12
Æ 
01:49 May 30, 2020
H6839
